ICER’s Final Evidence Report for Two Myasthenia Gravis Therapies Now Available
The Institute for Clinical and Economic Review (ICER) has published its final evidence report for two drugs used to treat [...]
Why Did Medicare Squander $600 Million on Efficacy-Free Cancer Drugs?
According to a new JAMA report, Medicare spent almost $600 million in three years on drugs used in oncology treatments. [...]
Part 2 of AmerisourceBergen Podcast on Insulin Biosimilars Now Available
Part two of AmerisourceBergen’s podcast series on insulin biosimilars is now available. This episode features guidance for pharmacies awaiting updated [...]
CMMI Director Discusses Aduhelm Coverage
Center for Medicare and Medicaid Innovation (CMMI) Director Elizabeth Fowler recently discussed Biogen’s Aduhelm drug. She noted that Congress first needs [...]
Chronic Disease Management Company Raises $100 Million in Series D Funding
Lark Health has announced $100 million in series D funding. The disease management startup uses artificial intelligence (AI) and healthcare [...]
American Drug Market Is a Pharma Cash Cow
A recent report considers the prescription drug prices of 20 top-selling drugs—both in the United States and worldwide. The trend [...]
New Whitepaper Highlights CMS-Compliant Price Comparison Tool
RxSavings Solutions is offering a new whitepaper that highlights its real-time benefit tool (RTBT) that compares drug prices. The pricing [...]
New Prescryptive Health PBM Reduces Drug Costs Using EHR Data and Promotes Transparency
Amid growing criticism regarding pharmacy benefit managers (PBMs), one new startup is entering the crowded space. Prescryptive Health aims to [...]
MMIT’s Q2 Update to 2021 Directory of Health Plans Now Available
MMIT has released an updated Directory of Health Plans that reflects key second-quarter trends, including shifting enrollment numbers, acquisitions, and [...]
Employer Healthcare Costs Will Increase 5% in 2022 as the COVID-19 Pandemic Continues
A recent report released by Willis Towers Watson notes an expected 5% increase in healthcare costs in 2022. Premiums and [...]
ICER VP of Research Recognized as Emerging Health Leader, Seeks to Improve Health Equity
Foluso Agboola, a Nigerian researcher who pursued her training at Harvard before joining the Institute for Clinical and Economic Review [...]
ICER’s Value Assessments Inform Pricing Decisions
Although new technologies have brought about novel therapies for previously unaddressed diseases, setting prices for these sometimes life-saving treatments remains [...]
Medicare Price Negotiation Idea Gaining Ground
Allowing Medicare to negotiate drug prices with pharma may soon become policy. A growing number of legislators have publicly expressed [...]
NICE Begins Construction of RWE Framework, Turns to Aetion for Guidance in Recent Collaboration
The National Institute for Health and Care Excellence (NICE) has begun working on new guidelines that will inform pharmaceutical companies [...]
Pharma Overhaul Would Reduce Drug Costs While Supporting Innovation
A recent article discusses the impact of legislation intended to lower drug prices on the pharmaceutical industry, such as price [...]
MedPAC Talks Value-Based Healthcare and International Reference Pricing As Aduhelm Cost Sounds Alarms
The Medicare Payment Advisory Commission (MedPAC) is considering a series of measures that would reduce healthcare costs, including international reference pricing [...]
CMMI Director Discusses Value-Based Care and Improving Health Equity
Center for Medicare and Medicaid Innovation (CMMI) Director Liz Fowler discussed value-based payment models and improving existing healthcare models in [...]
Podcast on Preparing for Insulin Biosimilar Approval Now Available
AmerisourceBergen has released part two of a podcast detailing how insulin biosimilars will affect pharmacies and patients. “In part two [...]
Part 3 of MHE Interview With Prime Therapeutics CEO and President Now Available
Managed Healthcare Executive recently interviewed Prime Therapeutics CEO and President Ken Paulus. Paulus details the benefits of Prime Therapeutics’ recent [...]
Major Corporations Weigh In As Drug Pricing Debate Continues
Major American corporations are split in half as the drug pricing debate continues. One camp, led by the U.S. Chamber [...]
New Report Estimates 30% in CMS Drug Savings Using Domestic Reference Pricing Model
A new report estimates that Medicare could have seen savings as high as 30% had a domestic reference pricing approach [...]
Prescription Drug Pricing Reform Could Mean Discounts on AAP Drugs Pending Clinical Proof
As multidisciplinary stakeholders consider how to reform the prescription drug pricing structure, one recent proposal is gaining traction. Drugs pushed [...]
Whitepaper on Effectively Preparing for CMS Price Transparency Mandates
A whitepaper on preparing for new Medicare price transparency legislation is now available. Sponsored by Rx Savings Solutions, the whitepaper [...]
Vanderbilt Researcher Discusses the Drug Pricing Controversy in KHN Podcast
In a recent KHN podcast, Dr. Stacie Dusetzina at Vanderbilt University shared her thoughts on the ongoing challenges in reducing [...]
Novo Nordisk Agrees to $100 Million Settlement in Insulin Pricing Suit
Novo Nordisk has agreed to a settlement in the amount of $100 million in an insulin pricing lawsuit led by [...]